Ensitrelvir NEW
| Price | $50 | $115 |
| Package | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-08 |
Product Details
| Product Name: Ensitrelvir | CAS No.: 2647530-73-0 |
| Purity: 99.78% | Supply Ability: 10g |
| Release date: 2026/06/08 |
Product Introduction
Bioactivity
| Name | Ensitrelvir |
| Description | Ensitrelvir (S-217622) is an orally active inhibitor of SARS-CoV-2 3CL protease with IC50 of 13 nM. |
| In vitro | The EC50 values for SARS-CoV and MERS-CoV were 0.21 and 1.4 μM respectively. In a cytopathic effect (cpe)-inhibition assay of SARS-CoV-2 infected VeroE6/TMPRSS2 cells, Ensitrelvir shows the EC50 values are approximately 0.4 μM for both wild-type virus and Alpha, Beta, Gamma and Delta variants[1]. |
| In vivo | Ensitrelvir inhibits intrapulmonary replication of SARS-CoV-2 in mice in a dose-dependent manner[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 7.58 mg/mL (14.25 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 75.76 mg/mL (142.44 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 7.58 mg/mL (14.25 mM), Solution. |
| Keywords | Virus Protease | variant | SARS-CoV-2 3CL | SARS-CoV | SARSCoV | SARS coronavirus | S217622 | S 217622 | oral | intrapulmonary replication | Inhibitor | inhibit | Ensitrelvir | COVID-19 |
| Inhibitors Related | Phenytoin sodium | Hydroxychloroquine | L-Lysine | L-Lysine hydrochloride | Chloroquine phosphate | Hydroxyurea | Chloroquine | α-Cyclodextrin | Ofloxacin | Vidarabine | Thymidine | Danthron |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Protease Inhibitor Library | Bioactive Compound Library Plus | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
-
CAS:527-07-1
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-06-26 | ||
| $20.00 |
VIP7Y
|
Jinan Jianfeng Chemical Co., Ltd
|
2026-06-26 | |
|
Wuhan Biocar Pharmacy CO.,Ltd.
|
2025-12-25 | |||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-12-01 | ||
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2025-08-21 | |||
|
VIP4Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2025-04-04 | ||
| $14.00 |
Wuhan Dujiang Industrial Co., Ltd.
|
2023-04-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY